ANI Pharmaceuticals, Inc. (ANIP) on Decifer

Decifer ranks ANIP number 271 of 277 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 6% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 44% a year, profits grew 437% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• It sits in a part of the market we are watching.
• It keeps issuing a lot of new shares, which dilutes its owners.
• Revenue up about 44% with profits up 437% looks strong, but modest returns around 6%, heavy share issuance, momentum of 7 out of 35, and no worldview role hold it back.

The current read

The evidence on ANIP lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: ANI Pharmaceuticals, Inc. operates in drug manufacturers - specialty & generic. That places it inside the Healthcare, Biotech & Devices story.

Read the full ANIP research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.